Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Relay Therapeutics Inc (RLAY)

Relay Therapeutics Inc (RLAY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
2.47 -0.15 (-5.73%) 04/01/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 2.49 +0.02 (+0.81%) 19:38 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.38
Day High
2.59
Open 2.58
Previous Close 2.62 2.62
Volume 2,732,500 2,732,500
Avg Vol 2,630,240 2,630,240
Stochastic %K 6.76% 6.76%
Weighted Alpha -74.22 -74.22
5-Day Change -0.49 (-16.55%) -0.49 (-16.55%)
52-Week Range 2.38 - 10.72 2.38 - 10.72
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 444,148
  • Shares Outstanding, K 169,522
  • Annual Sales, $ 10,010 K
  • Annual Income, $ -337,710 K
  • EBIT $ -372 M
  • EBITDA $ -379 M
  • 60-Month Beta 1.65
  • Price/Sales 46.08
  • Price/Cash Flow N/A
  • Price/Book 0.59

Options Overview Details

View History
  • Implied Volatility 272.77% ( -175.90%)
  • Historical Volatility 82.96%
  • IV Percentile 90%
  • IV Rank 45.91%
  • IV High 553.79% on 03/21/25
  • IV Low 34.23% on 05/30/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 51
  • Volume Avg (30-Day) 82
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 3,639
  • Open Int (30-Day) 7,424

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.51
  • Number of Estimates 7
  • High Estimate -0.47
  • Low Estimate -0.57
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +17.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.38 +4.00%
on 04/01/25
Period Open: 3.41
3.91 -36.83%
on 03/13/25
-0.94 (-27.57%)
since 02/28/25
3-Month
2.38 +4.00%
on 04/01/25
Period Open: 4.12
5.99 -58.76%
on 01/10/25
-1.65 (-40.05%)
since 12/31/24
52-Week
2.38 +4.00%
on 04/01/25
Period Open: 8.02
10.72 -76.96%
on 09/09/24
-5.55 (-69.20%)
since 04/01/24

Most Recent Stories

More News
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

RLAY : 2.47 (-5.73%)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences

RLAY : 2.47 (-5.73%)
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025

RLAY : 2.47 (-5.73%)
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

RLAY : 2.47 (-5.73%)
Relay Therapeutics Reports Promising Interim Data for RLY-2608 in 2L PI3Kα-Mutated Metastatic Breast Cancer

Relay Therapeutics reports positive interim data for RLY-2608 in metastatic breast cancer, supporting a pivotal study in 2025.Quiver AI SummaryRelay Therapeutics, Inc. has announced updated interim clinical...

RLAY : 2.47 (-5.73%)
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

RLAY : 2.47 (-5.73%)
Relay Therapeutics to Present Updated Clinical Data for RLY-2608 at San Antonio Breast Cancer Symposium

Relay Therapeutics will present updated clinical data for RLY-2608 in advanced breast cancer at the San Antonio Symposium.Quiver AI SummaryRelay Therapeutics, a clinical-stage precision medicine company,...

RLAY : 2.47 (-5.73%)
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium

RLAY : 2.47 (-5.73%)
Relay Therapeutics and Elevar Therapeutics Announce Global Licensing Agreement for Lirafugratinib, a Potential Best-in-Class FGFR2 Inhibitor

Elevar Therapeutics secures global rights to develop lirafugratinib, a promising FGFR2 inhibitor, with potential milestone payments for Relay Therapeutics.Quiver AI SummaryRelay Therapeutics and Elevar...

RLAY : 2.47 (-5.73%)
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors

RLAY : 2.47 (-5.73%)

Business Summary

Relay Therapeutics Inc. is a clinical-stage precision medicines company. It focuses on enhancing small molecule therapeutic discovery in targeted oncology. The company's product pipeline consist RLY-1971, RLY-4008 and RLY-PI3K1047 which are in clinical stage. Relay Therapeutics Inc. is based in Cambridge,...

See More

Key Turning Points

3rd Resistance Point 2.79
2nd Resistance Point 2.69
1st Resistance Point 2.58
Last Price 2.47
1st Support Level 2.37
2nd Support Level 2.27
3rd Support Level 2.16

See More

52-Week High 10.72
Fibonacci 61.8% 7.53
Fibonacci 50% 6.55
Fibonacci 38.2% 5.56
Last Price 2.47
52-Week Low 2.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies